ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Below is Validea's guru fundamental report for IMMUNOCORE HOLDINGS PLC - ADR (IMCR). Of the 22 guru strategies we follow, IMCR rates highest using our P/B Growth Investor model based on the ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

Immunocore Holdings PLC has a consensus price target of $76.24, established from looking at the 49 latest analyst ratings. The last 3 analyst ratings were released from Leerink Partners ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Immunocore Holdings (IMCR – Research Report). Roche Holding AG ...